Profile of lebrikizumab and its potential in the treatment of asthma

Producción científica: Review articlerevisión exhaustiva

17 Citas (Scopus)

Resumen

Interleukin (IL)-13 has been associated with multiple inflammatory features of asthma. It affects multiple cellular lines in asthma and is a key mediator in airway hyperreactivity and remodeling. Periostin, an extracellular protein, has been used as a surrogate marker of IL-13 activity and has been linked to airway remodeling by inducing subepithelial fibrosis. Lebrikizumab is a humanized monoclonal antibody that targets IL-13. Studies have demonstrated promising results with lebrikizumab therapy in asthma with regard to pulmonary function and exacerbation rates, especially on those patients with surrogate markers of T helper cell type 2-driven inflammation (ie, elevated immunoglobulin E levels, eosinophil counts, periostin levels). Lebrikizumab appears to be a safe therapy, but there are ongoing studies evaluating its efficacy and safety profile. Other therapies that target IL-13 and the receptor of IL-4/IL-13 have been studied, but future studies are needed to determine their role in the treatment of asthma.

Idioma originalEnglish (US)
Páginas (desde-hasta)87-92
Número de páginas6
PublicaciónJournal of Asthma and Allergy
Volumen8
DOI
EstadoPublished - ago 10 2015

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Huella

Profundice en los temas de investigación de 'Profile of lebrikizumab and its potential in the treatment of asthma'. En conjunto forman una huella única.

Citar esto